LEUKANET EV

Their core work

LEUKANET EV is a German registered association (eingetragener Verein) focused on hematological malignancies — blood cancers including leukemia, lymphoma, myelodysplastic syndromes, multiple myeloma, and childhood cancers. Their core contribution to EU research is providing access to real-life patient data and representing the patient/clinical network perspective in large-scale big data platforms for oncology. In both their H2020 projects, they contributed to the HARMONY Alliance — Europe's leading big data platform for hematological cancers — helping translate clinical and patient-reported outcomes into research-grade datasets. Their value to consortia lies in bridging the gap between patient networks, clinical practice, and data-driven hematology research.

What they specialise in

How they've shifted over time

In their first project (HARMONY, from 2017), LEUKANET's focus was clearly on patient data access and big data infrastructure — contributing real-life data on leukemia, lymphoma, myelodysplastic syndromes, and multiple myeloma into a centralized platform, with emphasis on outcome measures. By the time HARMONY PLUS launched in 2020, the vocabulary shifted toward translational medicine, molecular genetics, digital health outcomes, and business models — suggesting a move from data collection toward making that data scientifically and commercially actionable. The trajectory is from patient-data contributor to a network with growing competence in digital health innovation and the pathway from research to clinical/market application.

LEUKANET is moving from a data-contributing patient network toward an organization with capabilities in digital health outcome frameworks and translational pathways, making them increasingly relevant for projects that need both patient community access and a bridge to clinical or commercial application.

How they like to work

LEUKANET has participated exclusively as a consortium partner — never as project coordinator — across both their H2020 projects, both of which are continuations of the same HARMONY Alliance. This suggests a focused, loyal contributor role within a trusted long-term consortium rather than a broad project-shopping strategy. With 57 unique partners across 13 countries gained through just two projects, they are clearly embedded in a large, active European network centered on the HARMONY ecosystem.

LEUKANET has built connections with 57 unique consortium partners across 13 countries through participation in the HARMONY Alliance — a notably wide network for an organization with only two projects, reflecting the scale of the HARMONY big data consortia. Their network is primarily European and centered on hematology research institutions, clinical centers, and oncology-focused organizations.

What sets them apart

LEUKANET is a specialized German NGO with direct ties to the patient and clinical community for blood cancers — a profile that is rare among research participants and highly sought after in health data projects requiring patient-reported outcomes and real-world evidence. Their sustained involvement in both phases of the HARMONY Alliance gives them institutional knowledge of Europe's most significant hematological malignancy big data infrastructure. For any consortium building in blood cancer research, digital oncology, or rare disease data platforms, LEUKANET brings community legitimacy and data access that a university or hospital alone cannot provide.

Highlights from their portfolio

• HARMONY
  The flagship European big data platform for hematological malignancies, receiving the maximum €500,000 in EC funding and establishing LEUKANET's central role in real-life patient data collection across six cancer types.
• HARMONY PLUS
  The follow-on phase extending HARMONY's platform with translational medicine and digital health outcome capabilities, confirming LEUKANET as a long-term structural partner in Europe's hematology data ecosystem.